Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension



Rating:

Share or cite this content

Citations should be made in the following way:
O. Bikou (New York, United States of America), S. Tharakan (New York, United States of America), K. Yamada (New York, United States of America), T. Kariya (New York, United States of America), J. Aguero (New York, United States of America), K. Fish (New York, United States of America), K. Ishikawa (New York, United States of America). SERCA2a gene therapy ameliorates pulmonary hypertension in a pig model: comparison of different delivery methods and therapeutic effect. 3555

Member's Comments

No comment yet.

Related content which might interest you: The effect of combined therapy using rosuvastatin and dihydroarteminin in a pulmonary malaria mouse model. Source: International Congress 2018 – Role of microbial exposure and inflammation in lung injury Year: 2018 Gene therapeutic approaches: from stem cell therapy to gene delivery Source: Annual Congress 2006 - Pulmonary hypertension at the crossroads of science and clinical medicine Year: 2006 Effect of long-term imatinib treatment in a severe preclinical PAH rat model: An insight into pulmonary perfusion using a novel casting method Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology Year: 2012 Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 VEGF gene transfer enhances fibrosis but improves pulmonary hemodynamics in experimental pulmonary fibrosis Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Targeted gene delivery of BMPR2 attenuates pulmonary hypertension Source: Eur Respir J 2012; 39: 329-343 Year: 2012 Comparison of different vasodilators in a model of secondary pulmonary hypertension (PH): Desaturation effects Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Improvement of exercise capacity due to beta blocker treatment in the model of MCT induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Optimal management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 254-261 Year: 2011 Beyond a single pathway: combination therapy in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 408-417 Year: 2016 Macitentan treatment improves the dysfunctional right ventricle in a sugen/hypoxic rat model of pulmonary hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019